Enriching cancer pharmacology with drugs of marine origin
Citations Over TimeTop 1% of 2019 papers
Abstract
Marine natural products have proven, over the last half-century, to be effective biological modulators. These molecules have revealed new targets for cancer therapy as well as dissimilar modes of action within typical classes of drugs. In this scenario, innovation from marine-based pharmaceuticals has helped advance cancer chemotherapy in many aspects, as most of these are designated as first-in-class drugs. Here, by examining the path from discovery to development of clinically approved drugs of marine origin for cancer treatment-cytarabine (Cytosar-U®), trabectedin (Yondelis®), eribulin (Halaven®), brentuximab vedotin (Adcetris®), and plitidepsin (Aplidin®)- together with those in late clinical trial phases-lurbinectedin, plinabulin, marizomib, and plocabulin-the present review offers a critical analysis of the contributions given by these new compounds to cancer pharmacotherapy.
Related Papers
- → Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin(2017)61 cited
- → Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?(2017)15 cited
- → An effective treatment of a late-line trabectedin for relapsed leiomyosarcoma(2017)
- [The Role of Novel Agents in the Treatment of Soft Tissue Sarcoma].(2017)
- → Long-term efficacy of eribulin in patients with advanced myxoid liposarcoma resistant to trabectedin: A case report(2024)